Key facts
- It has raised $30.0M across 1 recorded rounds; the latest was Early Stage VC ($10.0M) in Dec 2023.
- PranaX has filed 1 Form D with the SEC, most recently Jan 2024 ($10.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for PranaX
Funding rounds
1 roundsAbout PranaX
Developer of exosome-based natural supplements and wellness products designed to activate the body's natural cellular regeneration processes. The company's products harness the power of cellular rejuvenation to combat age-related decline and help reduce inflammation, improve cognitive function, and boost the immune system, enabling individuals to take control of their health and optimize their well-being throughout their lifespan.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2022
- Employees
- 12
- Website
- pranax.com/
- Ownership
- Privately Held (backing)
PranaX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PranaX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PranaX in its N-PORT filings yet. We sweep new filings monthly.